Fludarabine triphosphate (trisodium)

Fludarabine triphosphate (F-ara-ATP) trisodium, the active metabolite of Fludarabine (HY-B0069), is a potent, noncompetitive and specific inhibitor of DNA primase, with an IC50 of 2.3 μM and a Ki of 6.1 μM. Fludarabine triphosphate trisodium inhibits DNA synthesis by blocking DNA primase and primer RNA formation. Fludarabine triphosphate trisodium inhibits ribonucleotide reductase and DNA polymerase and ultimately leads to cellular apoptosis[1][2].

Product Specifications

Product Name Alternative

F-ara-ATP (trisodium)

UNSPSC

12352005

Target

Apoptosis; DNA/RNA Synthesis; Drug Metabolite; Nucleoside Antimetabolite/Analog

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/fludarabine-triphosphate-trisodium.html

Concentration

100 mM * 84.59 μL in Water

Purity

99.98

Solubility

H2O : 125 mg/mL (ultrasonic)

Smiles

O[C@@H]([C@@H]1O)[C@](O[C@@H]1CO[P](O[P](O[P](O)(O[Na])=O)(O[Na])=O)(O[Na])=O)([H])N2C3=NC(F)=NC(N)=C3N=C2

Molecular Formula

C10H12FN5Na3O13P3

Molecular Weight

591.12

References & Citations

[1]Catapano CV, et al. Inhibition of primer RNA formation in CCRF-CEM leukemia cells by fludarabine triphosphate. Cancer Res. 1991 Apr 1;51 (7) :1829-35. |[2]Woodahl EL, et al. A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients. Cancer Chemother Pharmacol. 2009 Feb;63 (3) :391-401.